Sign in
Taking people in United StatesPhase 2

Compares two insulins in pregnant women with diabetes

Compares insulin detemir and NPH insulin in pregnant women with diabetes.

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
DETERMINE: Detemir vs NPH
Status
Recruiting
Phase
Phase 2
People taking part
336 people, planned
Started
1 Feb 2022
Planned end
Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Insulin Detemir
  • Insulin NPH
Record updated
26 September 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with type 2 diabetes or gestational diabetes who need insulin. It compares two long-acting insulins, detemir and NPH.

Age
18 years or older
Sex
All sexes (pregnant women)
Disease stage
Pregnant, with type 2 diabetes that was there before pregnancy or gestational diabetes, and needing insulin for blood sugar control
Earlier treatment
Cannot have needed insulin before becoming pregnant

Main reasons for not taking part

  • Twin or other multiple pregnancy
  • Type 1 diabetes
  • Known allergy to NPH or insulin detemir
  • Known major fetal malformations
  • Known HIV, hepatitis B or hepatitis C

This trial only enrols pregnant participants. The registry sentence this rests on: Inclusion criteria will include pregnant women with pre-existing T2DM and GDM who requiring insulin to manage their blood sugars in pregnancy.

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Inclusion criteria will include pregnant women with pre-existing T2DM and GDM who requiring insulin to manage their blood sugars in pregnancy

Who cannot take part

  • Indication for planned premature delivery (placenta accrete, or prior classical cesarean delivery)
  • Type 1 Diabetes mellatus
  • Known or suspected hypersensitivity to NPH or insulin detemir
  • Chronic renal or hepatic insufficiency
  • Known to be HIV, Hepatitis B, or Hepatitis C positive
  • Age < 18
  • Multiple Gestation
  • Known fetal major malformations
  • Insulin dependent before conception

Where in United States

  • University of California, Los AngelesLos Angeles, United StatesContact: Christina S Han, MDTaking people

About the trial

What the trial wants to find out

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

The 2 groups in the trial

  • Insulin DetemirTreatment being tested

    Patients are to receive insulin detemir as long acting insulin to control blood sugars

  • Insulin NPHExisting treatment, for comparison

    Patients are to receive insulin NPH as long acting insulin to control blood sugars

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study
Plain-language title
Compares two insulins in pregnant women with diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 September 2023